CY1114969T1 - Crystalline form of 1- (β-D-glycopyranosyl) -4-methyl- 3- [5- (4-fluorophenyl) -2- thienylmethyl] benzene - Google Patents

Crystalline form of 1- (β-D-glycopyranosyl) -4-methyl- 3- [5- (4-fluorophenyl) -2- thienylmethyl] benzene

Info

Publication number
CY1114969T1
CY1114969T1 CY20141100129T CY141100129T CY1114969T1 CY 1114969 T1 CY1114969 T1 CY 1114969T1 CY 20141100129 T CY20141100129 T CY 20141100129T CY 141100129 T CY141100129 T CY 141100129T CY 1114969 T1 CY1114969 T1 CY 1114969T1
Authority
CY
Cyprus
Prior art keywords
glycopyranosyl
thienylmethyl
fluorophenyl
methyl
crystalline form
Prior art date
Application number
CY20141100129T
Other languages
Greek (el)
Inventor
Sumihiro Nomura
Eiji Kawanishi
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07850306.7A external-priority patent/EP2102224B2/en
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of CY1114969T1 publication Critical patent/CY1114969T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μια νέα κρυσταλλική μορφή ημιένυδρου 1-(β-D-γλυκοπυρανοζυλο)-4-μεθυλο-3-[5- (4-φθοροφαινυλο)-2-θειενυλομεθυλο]βενζολίου, η οποία έχει ευνοϊκά χαρακτηριστικά, χαρακτηρίζεται από το χαρακτηριστικό διάγραμμα περίθλασης ακτίνων Χ από σκόνη και/ή από το φάσμα υπερύθρου αυτής.A novel crystalline form of 1- (β-D-glycopyranosyl) -4-methyl-3- [5- (4-fluorophenyl) -2-thienylmethyl] benzene hemihydrate, which has favorable characteristics, is characterized by the X-ray diffraction pattern. from dust and / or its infrared spectrum.

CY20141100129T 2006-12-04 2014-02-19 Crystalline form of 1- (β-D-glycopyranosyl) -4-methyl- 3- [5- (4-fluorophenyl) -2- thienylmethyl] benzene CY1114969T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86842606A 2006-12-04 2006-12-04
JP2006327019 2006-12-04
EP07850306.7A EP2102224B2 (en) 2006-12-04 2007-12-03 CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE

Publications (1)

Publication Number Publication Date
CY1114969T1 true CY1114969T1 (en) 2016-12-14

Family

ID=58464035

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100129T CY1114969T1 (en) 2006-12-04 2014-02-19 Crystalline form of 1- (β-D-glycopyranosyl) -4-methyl- 3- [5- (4-fluorophenyl) -2- thienylmethyl] benzene

Country Status (1)

Country Link
CY (1) CY1114969T1 (en)

Similar Documents

Publication Publication Date Title
AR118450A2 (en) CRYSTALLINE FORM OF 1- (b-D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-THENYLMEthyl] BENZENE HEMIHYDRATE
CY1122646T1 (en) BICYCLIC HETEROARYL COMPOUNDS
CY1119534T1 (en) Phosphorus derivatives as kinase inhibitors
CY1122895T1 (en) 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-CYCLOPANECARBOXAMIDO)-3-METHYLPYRIDIN-3-YL)-BENZOIC ACID SOLID
CU23774A3 (en) ALFA-ENAC EXPRESSION ARNI INHIBITION
NI200800294A (en) NEW CRYSTALLINE VI FORM OF AGOMELATIN, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
BRPI0711889B8 (en) method for making simvastatin, composition of matter, method of making huvastatin, method of making simvastatin, and method of making a composition of matter of simvastatin or huvastatin
CY1115738T1 (en) CRYSTALLY SOLVED SOLUTIONS OF PRODUCERS (1S) -1,5-ANYΔPO-1-C- (3 - (((FYANYL) METHYL) FINYL) -D-GLUCITOLIS SULPH
CY1114575T1 (en) DIMETOXY ACETON SOLUTION SOLUTION AND ITS PREPARATION PROCEDURE
CY1115426T1 (en) 1,3-DIMUNATED IMIMAZOLIDIN-2-ONE PRODUCERS AS INPUTS TOY CYP 17
EA200601273A1 (en) NEW CRYSTAL FORM V AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
CY1112781T1 (en) 2'-FLUORO-2'-DEOXYTETRAHYROIDURIDES AS CYTIDINE DISEASE INHIBITORS
BRPI0914802A2 (en) Compound, prodrug, drug, use of the compound or a prodrug thereof.
EA200601271A1 (en) NEW CRYSTAL FORM IV OF AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
CY1114669T1 (en) Substituted Sulfonamide Derivatives
EA200802111A1 (en) IMPLANTS FOR THE TREATMENT OF THE STATES ASSOCIATED WITH DOPAMIN
EA200971068A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
FR2884426B1 (en) INSTALLATION FOR THE STERILIZATION OF OBJECTS BY ELECTRON BOMBING.
MX2007010143A (en) Crystalline forms of linezolid intermediate.
CL2007002388A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of hemangiomas or hemangioblastomas.
CY1114969T1 (en) Crystalline form of 1- (β-D-glycopyranosyl) -4-methyl- 3- [5- (4-fluorophenyl) -2- thienylmethyl] benzene
NI200900113A (en) CRYSTALLINE FORM OF 1- (Beta-D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-THENYLMETHYL] BENZENE HEMIHYDRATE.
AR047175A1 (en) METHOD FOR THE TREATMENT OF PULMONARY DISEASES
MA33932B1 (en) DERIVATIVES OF 2-ALDOXIMINO-5-FLUOROPYRIMIDINE
HN2009001135A (en) CRYSTALLINE SHAPE OF THE HEMIHYDRATE OF 1- (B-D-GLUCOPIRANOSIL) - 4-METHYL, 3- {5- (4-FLUOROPHENYL) -2-TIENYLMETIL} BENZENE